Reference

1. Dolovich, Myrna B., and Rajiv Dhand. "Aerosol drug delivery: developments in device design and clinical use." The Lancet 377.9770 (2011): 1032-1045.
2. Uddin, Md, et al. "Pharmacopoeial standards and specifications for pharmaceutical aerosols: In-process and finished products quality control tests." Advances in Research 6.3 (2016): 1-12.
3. Shetty, A. D. V. A. I. T., and G. A. N. G. A. Srinivasan. "Advancements in dry powder inhaler." Asian J Pharm Clin Res 10.2 (2017): 8-12.
4. Tiwari, Gaurav, et al. "Drug delivery systems: An updated review." International journal of pharmaceutical investigation 2.1 (2012): 2.
5. Myers, Timothy R. "Year in review 2014: aerosol delivery devices." Respiratory Care 60.8 (2015): 1190-1196.
6. Cazzola, Mario, et al. "Tiotropium formulations and safety: a network meta-analysis." Therapeutic Advances in Drug Safety 8.1 (2017): 17-30.
7. Usmani, Omar S. "Treating the small airways." Respiration 84.6 (2012): 441-453.
8. Andrade, Fernanda, et al. "Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases." Advanced drug delivery reviews 65.13-14 (2013): 1816-1827.
9. Lavorini, Federico. "The challenge of delivering therapeutic aerosols to asthma patients." International Scholarly Research Notices 2013 (2013).
10. Kulkarni, Vitthal S., and Charles Shaw. Essential chemistry for formulators of semisolid and liquid dosages. Academic Press, 2015.
11. Sciarra, John J., Christopher J. Sciarra, and Updated by Staff. "Aerosol technology." Kirk?Othmer Encyclopedia of Chemical Technology (2000): 1-20.
12. Shinde, Namdeo G., et al. "Pharmaceutical foam drug delivery system: General considerations." Indo Am. J. Pharm. Res 3 (2013): 1322-1327.
13. Allen Jr, Loyd V. "Dosage form design and development." Clinical therapeutics 30.11 (2008): 2102-2111.
14. Hinds, William C., and Yifang Zhu. Aerosol technology: properties, behavior, and measurement of airborne particles. John Wiley & Sons, 2022.
15. Wang, Hui, et al. "Design and pharmaceutical applications of a low-flow-rate single-nozzle impactor." International Journal of Pharmaceutics 533.1 (2017): 14-25.
16. Colbeck, I., and Mihalis Lazaridis. Aerosol Science. Wiley Online Library, 2014.
17. Usmani, Omar S., Martyn F. Biddiscombe, and Peter J. Barnes. "Regional lung deposition and bronchodilator response as a function of ?2-agonist particle size." American journal of respiratory and critical care medicine 172.12 (2005): 1497-1504.
18. Darquenne, Chantal, et al. "Bridging the gap between science and clinical efficacy: physiology, imaging, and modeling of aerosols in the lung." Journal of aerosol medicine and pulmonary drug delivery 29.2 (2016): 107-126.
19. Tena, Ana Fernández, and Pere Casan Clarà. "Deposition of inhaled particles in the lungs." Archivos de Bronconeumología (English Edition) 48.7 (2012): 240-246.
20. Worth Longest, P., and Michael Hindle. "Numerical model to characterize the size increase of combination drug and hygroscopic excipient nanoparticle aerosols." Aerosol Science and Technology 45.7 (2011): 884-899.
21. Martin, Andrew R., and Warren H. Finlay. "The effect of humidity on the size of particles delivered from metered-dose inhalers." Aerosol science and technology 39.4 (2005): 283-289.
22. Javaheri, Emadeddin, and Warren H. Finlay. "Size manipulation of hygroscopic saline droplets: Application to respiratory drug delivery." International Journal of Heat and Mass Transfer 67 (2013): 690-695.
23. Guo, Yushen, Evgenyi Shalaev, and Scott Smith. "Physical stability of pharmaceutical formulations: solid-state characterization of amorphous dispersions." TrAC Trends in Analytical Chemistry 49 (2013): 137-144.
24. Huang, Jun, Chimanlall Goolcharran, and Krishnendu Ghosh. "A quality by design approach to investigate tablet dissolution shift upon accelerated stability by multivariate methods." European Journal of Pharmaceutics and Biopharmaceutics 78.1 (2011): 141-150.
25. Karathanasis, Efstathios, et al. "Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery." Journal of Controlled Release 103.1 (2005): 159-175.
26. Loira-Pastoriza, Cristina, Julie Todoroff, and Rita Vanbever. "Delivery strategies for sustained drug release in the lungs." Advanced drug delivery reviews 75 (2014): 81-91.
27. Lee, Wing-Hin, et al. "Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges." Asian journal of pharmaceutical sciences 10.6 (2015): 481-489.
28. Leach, Chet L. "The CFC to HFA transition and its impact on pulmonary drug development." Respiratory care 50.9 (2005): 1201-1208.
29. Shieh, D., Huitt, D., Kennedy, T., Gopegui, R., 2008. US 7,448,517 B2. US 7,448,517 B2.
30. Stein, Stephen W., and Charles G. Thiel. "The history of therapeutic aerosols: a chronological review." Journal of aerosol medicine and pulmonary drug delivery 30.1 (2017): 20-41.
31. Rogueda, Philippe, et al. "Twenty years of HFA pMDI patents: facts and perspectives." Journal of Pharmacy and Pharmacology 64.9 (2012): 1209-1216.
32. Stein, Stephen W., et al. "Advances in metered dose inhaler technology: hardware development." Aaps Pharmscitech 15 (2014): 326-338.
33. Van den Berge, M., et al. "Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma." Allergy 68.1 (2013): 16-26.
34. Kadam, Praful, Hema Kanekar, and Anubha Khale. "Pulmonary drug delivery system: current practices and applications." World J. Pharm. Res 3.6 (2014): 204-229.
35. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, International Agency for Research on Cancer, and World Health Organization. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. Vol. 82. World Health Organization, 2002.